Management of gouty arthritis in patients with chronic kidney disease.

Abstract

Chronic kidney disease (CKD) is a comorbid condition that affects, based on recent estimates, between 47% and 54% of patients with gouty arthritis. However, data from randomized controlled trials in patients with gouty arthritis and CKD are limited, and current gouty arthritis treatment guidelines do not address the challenges associated with managing this patient population. Nonsteroidal anti-inflammatory drugs and colchicine are recommended first-line treatments for acute gouty arthritis attacks. However, in patients with CKD, nonsteroidal anti-inflammatory drugs are not recommended because their use can exacerbate or cause acute kidney injury. Also, colchicine toxicity is increased in patients with CKD, and dosage reduction is required based on level of kidney function. Allopurinol, febuxostat, and pegloticase are all effective treatments for controlling elevated uric acid levels after the treatment of an acute attack. However, in patients with CKD, required allopurinol dosage reductions may limit efficacy; pegloticase requires further investigation in this population, and febuxostat has not been studied in patients with creatinine clearance<30 mL/min. This article reviews the risks and benefits associated with currently available pharmacologic agents for the management of acute and chronic gouty arthritis including urate-lowering therapy in patients with CKD. Challenges specific to primary care providers are addressed, including guidance to help them decide when to collaborate with, or refer patients to, rheumatology and nephrology specialists based on the severity of gout and CKD.

• Authors: Abdul A Abdellatif, Naser Elkhalili
• Journal: American journal of therapeutics (Am J Ther) 2014 Nov-Dec Vol. 21 Issue 6 Pg. 523-34 ISSN: 1536-3686 [Electronic] United States
• PMID: 22960848 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Anti-Inflammatory Agents, Non-Steroidal
• Gout Suppressants
• Colchicine

Topics

• Acute Disease
• Anti-Inflammatory Agents, Non-Steroidal (adverse effects, therapeutic use)
• Arthritis, Gouty (complications, drug therapy, physiopathology)
• Chronic Disease
• Colchicine (administration & dosage, therapeutic use)
• Gout Suppressants (adverse effects, therapeutic use)
• Humans
• Practice Guidelines as Topic
• Renal Insufficiency, Chronic (complications, drug therapy, physiopathology)
• Severity of Illness Index